OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.
SyntaxBio
Seed Round in 2024
SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
Outpace Bio
Series B in 2024
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Foresight Diagnostics
Series B in 2024
Foresight Diagnostics is a biotechnology company that specializes in developing a novel liquid biopsy test aimed at measuring minimal residual disease to enhance patient management in oncology. The company focuses on early cancer detection through a simple blood sample, leveraging the unique biological features that distinguish cancer cells from healthy cells. This innovative approach enables healthcare professionals to diagnose smaller tumors at an earlier stage, facilitating personalized and effective treatment strategies for patients. Foresight Diagnostics has attracted significant interest from multiple pharmaceutical companies, underscoring its potential impact in the field of cancer diagnostics and treatment.
BillionToOne
Series D in 2024
BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.
Aikium
Pre Seed Round in 2024
Aikium is a biotechnology company that specializes in developing novel protein therapeutics for neuro-inflammation and oncology. It combines advancements in synthetic biology and deep learning to create unique, non-antibody scaffold proteins that specifically target and bind to disordered regions of proteins, offering innovative solutions for clients to effectively address disordered proteins.
Catena Biosciences
Seed Round in 2024
Catena Biosciences is a biotechnology firm focused on advancing protein conjugation technology to address autoimmune disorders and other medical challenges. The company specializes in a method that facilitates the rapid and selective attachment of proteins, utilizing natural amino acids such as tyrosine and cysteine. This innovative approach allows researchers to develop novel therapeutics across various fields, including autoimmune disorders, oncology, and vaccine development. By streamlining the process of building biologic structures, Catena Biosciences aims to enhance medical research and contribute to the creation of effective treatments.
OverT Bio
Seed Round in 2024
OverT Bio is a biotechnology company focused on developing cell therapies for cancer treatment. The company specializes in identifying and creating novel genetic modifications that empower immune cells to navigate and overcome the obstacles posed by tumors. Through its innovative approach, OverT Bio aims to enhance the effectiveness and durability of immunotherapies, contributing to advancements in cancer identification and treatment within the healthcare sector.
Insamo is a biotechnology company focused on the discovery and development of membrane-permeable and orally available cyclic peptides that possess antibody-like binding affinity. The company utilizes an innovative platform that combines molecular biology and parallel synthetic chemistry to design, synthesize, and test these cyclic peptides at an unprecedented scale. By rapidly identifying preclinical candidates with favorable pharmacological properties, Insamo aims to transform patient care by providing alternatives to injected or infused biologics, thereby facilitating easier administration through oral formulations.
Aperiam Bio
Seed Round in 2023
Aperiam Bio, founded in 2021 and based in Austin, Texas, specializes in the development of industrial and therapeutic proteins. The company collaborates with enzyme engineers and distributors to produce stabilized, solubilized, and catalytically optimized proteins. Utilizing advanced deep learning optimization and proprietary algorithms, Aperiam Bio identifies critical components of protein chemistry to discover novel gain-of-function mutations. This innovative approach allows the engineering of biological molecules aimed at enhancing agricultural and pharmaceutical applications. By focusing on hyper-folded proteins, Aperiam Bio enables researchers to create more effective and durable proteins than those found in nature, ultimately contributing to advancements in various fields and improving lives.
DermBiont
Series B in 2023
DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and based in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to compete with pathogenic organisms such as fungi, bacteria, and viruses. DermBiont's product portfolio includes therapeutics for various skin conditions, including fungal infections and hyperpigmentation disorders like melasma, as well as treatments for seborrheic keratoses. The company employs a unique discovery platform that utilizes its skin microbiome library, integrating prebiotics, probiotics, and postbiotics to develop innovative topical therapies with defined mechanisms of action.
Range Biotechnologies
Seed Round in 2023
Range Biotechnologies is a developer of translational proteomics technology aimed at advancing human health. The company focuses on creating innovative tools that enable personalized health by allowing for the precise measurement of multiple proteins across numerous samples simultaneously. This capability provides healthcare professionals with critical insights into the fundamental mechanisms of diseases and their evolution over time, facilitating a deeper understanding of health conditions and informing more effective treatment strategies.
Siren Biotechnology
Seed Round in 2023
Siren Biotechnology is a biotech company focused on developing innovative cancer treatments through a unique platform that integrates AAV gene therapy with cytokine immunotherapy. By combining these two transformative therapeutic approaches, Siren aims to address significant challenges in cancer treatment, such as delivery, efficacy, and toxicity. This novel modality seeks to enhance the elimination of tumor cells while simultaneously stimulating anti-tumor immunity, thereby offering a promising new strategy for cancer therapy. Through this integrated approach, Siren Biotechnology aspires to advance the effectiveness of cancer treatments and improve patient outcomes.
Foresight Diagnostics
Series B in 2023
Foresight Diagnostics is a biotechnology company that specializes in developing a novel liquid biopsy test aimed at measuring minimal residual disease to enhance patient management in oncology. The company focuses on early cancer detection through a simple blood sample, leveraging the unique biological features that distinguish cancer cells from healthy cells. This innovative approach enables healthcare professionals to diagnose smaller tumors at an earlier stage, facilitating personalized and effective treatment strategies for patients. Foresight Diagnostics has attracted significant interest from multiple pharmaceutical companies, underscoring its potential impact in the field of cancer diagnostics and treatment.
Sensible Biotechnologies
Pre Seed Round in 2023
Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.
Outpace Bio
Series A in 2023
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Wyndly is a company that specializes in personalized allergy treatment and online care. It offers clinically tested therapies designed to provide long-term relief from allergies. Wyndly's expert providers work closely with clients to develop tailored treatment plans that address the root causes of allergies, which are often not effectively managed by traditional antihistamines and nasal sprays. The company's innovative approach includes the use of allergy drops, which aim to deliver a more affordable and convenient form of immunotherapy. Overall, Wyndly focuses on enhancing the quality of life for individuals suffering from allergies by offering effective, customized solutions.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company specializes in the development of a novel technology that allows for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. Evonetix aims to enhance DNA synthesis accuracy and scalability, making it accessible to researchers and transforming how DNA is produced and utilized for gene synthesis. With a highly experienced engineering team that combines expertise from various scientific and engineering disciplines, Evonetix is positioned to significantly impact the capabilities of synthetic biology by enabling applications that were previously unfeasible.
Kernal Biologics
Series A in 2022
Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.
BillionToOne
Series C in 2022
BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.
Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.
DermBiont
Series A in 2021
DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and based in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to compete with pathogenic organisms such as fungi, bacteria, and viruses. DermBiont's product portfolio includes therapeutics for various skin conditions, including fungal infections and hyperpigmentation disorders like melasma, as well as treatments for seborrheic keratoses. The company employs a unique discovery platform that utilizes its skin microbiome library, integrating prebiotics, probiotics, and postbiotics to develop innovative topical therapies with defined mechanisms of action.
Klivo Health is a health technology company focused on enhancing the quality of life for individuals with chronic diseases. The company operates a patient management platform designed to empower users to manage their health effectively. By providing real-time monitoring of medical conditions and facilitating the transmission of critical health data, such as blood glucose levels, Klivo Health enables healthcare professionals to achieve improved clinical outcomes. The platform also offers users access to information regarding clinical conditions and dietary guidance. Through its innovative approach, Klivo Health aims to add life to years rather than merely extending lifespan.
Teiko.bio
Venture Round in 2021
Teiko.bio is an immune profiling company founded in 2020 and based in Salt Lake City, Utah. The company has developed a platform that identifies immune features linked to patient response, assesses the abundance and activation scores of various immune cell types, and suggests rational targets for combination therapies. By enabling clinicians to make informed treatment decisions, Teiko.bio aims to enhance patient outcomes and facilitate new discoveries in therapeutic pathways.
OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.
Axonis Therapeutics
Venture Round in 2021
Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting the KCC2, a key mediator of inhibition in the brain. The company leverages groundbreaking research from institutions such as Boston Children’s Hospital, Harvard, and Laval University to create a proprietary neuron-specific K-Cl cotransporter discovery engine. This innovative platform aims to enhance the treatment of various conditions, including epilepsy, pain, and other central nervous system pathologies, by fine-tuning neuronal inhibition. Through its efforts, Axonis Therapeutics seeks to contribute to the healthcare industry's ability to combat neurodegeneration, restore neuronal excitation, and promote neuron regeneration, ultimately improving the quality of life for individuals affected by these disorders.
Glyphic Biotechnologies
Seed Round in 2021
Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.
Foresight Diagnostics
Series A in 2021
Foresight Diagnostics is a biotechnology company that specializes in developing a novel liquid biopsy test aimed at measuring minimal residual disease to enhance patient management in oncology. The company focuses on early cancer detection through a simple blood sample, leveraging the unique biological features that distinguish cancer cells from healthy cells. This innovative approach enables healthcare professionals to diagnose smaller tumors at an earlier stage, facilitating personalized and effective treatment strategies for patients. Foresight Diagnostics has attracted significant interest from multiple pharmaceutical companies, underscoring its potential impact in the field of cancer diagnostics and treatment.
Catena Biosciences
Pre Seed Round in 2021
Catena Biosciences is a biotechnology firm focused on advancing protein conjugation technology to address autoimmune disorders and other medical challenges. The company specializes in a method that facilitates the rapid and selective attachment of proteins, utilizing natural amino acids such as tyrosine and cysteine. This innovative approach allows researchers to develop novel therapeutics across various fields, including autoimmune disorders, oncology, and vaccine development. By streamlining the process of building biologic structures, Catena Biosciences aims to enhance medical research and contribute to the creation of effective treatments.
uLab Systems
Series E in 2021
uLab Systems Inc. is a technology company specializing in digital dental treatment planning for orthodontists. Established in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, uLab has developed a sophisticated software platform that allows orthodontists to create customized treatment plans and aligner movement strategies. The company's proprietary technology employs artificial intelligence and fully automated features, enabling orthodontists to efficiently generate chairside treatment plans in under five minutes. This innovation not only streamlines the treatment process but also helps in reducing lab fees and expediting the delivery of custom aligners. Through its solutions, uLab Systems enhances the efficiency and effectiveness of orthodontic care.
Outpace Bio
Series A in 2021
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Kit.com
Seed Round in 2020
Kit.com is a company that specializes in at-home medical testing solutions, providing health testing kits designed to facilitate preventative health assessments across various industries. By enabling insurers and telehealth companies to offer convenient testing options, Kit.com aims to enhance patient access to essential health services from the comfort of their homes. The company's offerings include comprehensive testing services that serve as safe and reliable alternatives to traditional doctor and laboratory visits. Additionally, Kit.com is involved in supplying a diverse range of products, including electronics and sporting goods, available for online shopping, thereby addressing customer inquiries through multiple channels such as phone, email, and online applications.
R-Zero is a company specializing in smart building technology and biosafety solutions aimed at enhancing indoor environments. It offers a suite of products designed to improve workforce productivity and optimize real estate utilization while promoting health and safety. R-Zero's portfolio includes advanced indoor air quality and comfort monitoring systems, high-efficiency HVAC filtration, occupancy-based building controls, and space utilization sensors. Additionally, the company provides mobile UV-C units that effectively disinfect large spaces, aiding in the reduction of infectious disease transmission. With a focus on operational efficiency, R-Zero's connected platform delivers real-time insights that empower building owners and operators to adapt their properties for future demands while ensuring a safe and productive environment for tenants.
BillionToOne
Series A in 2020
BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company specializes in the development of a novel technology that allows for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. Evonetix aims to enhance DNA synthesis accuracy and scalability, making it accessible to researchers and transforming how DNA is produced and utilized for gene synthesis. With a highly experienced engineering team that combines expertise from various scientific and engineering disciplines, Evonetix is positioned to significantly impact the capabilities of synthetic biology by enabling applications that were previously unfeasible.
Fluent BioSciences
Series A in 2020
Fluent BioSciences is a life science technology company focused on single-cell molecular analysis, eliminating the need for complex microfluidic instrumentation. The company’s proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions. This innovative approach allows for sensitive and unbiased preparation of proteins and nucleic acids, enhancing sequencing applications. By making single-cell and molecular analysis more accessible, Fluent BioSciences enables a broader range of researchers in biotechnology, pharmaceuticals, and academic institutions to conduct advanced analyses, thereby expanding market opportunities within the life sciences field.
Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.
Gali Health
Seed Round in 2019
Gali Health, Inc. is a health technology company based in San Francisco, California, founded in 2015. The company has developed a mobile application called Gali, which serves as a personal health assistant aimed at individuals with chronic conditions. Gali leverages collective intelligence and artificial intelligence to analyze health data, providing users with personalized support regarding medical, lifestyle, and psychological aspects of managing their health. The platform focuses on empowering users by crowdsourcing health information and delivering medically-validated insights, enabling proactive health management. Gali Health's mission is to ensure that individuals dealing with chronic illnesses do not feel isolated or powerless, advancing consumer-driven healthcare through innovative technology.
DermBiont
Series A in 2019
DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and based in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to compete with pathogenic organisms such as fungi, bacteria, and viruses. DermBiont's product portfolio includes therapeutics for various skin conditions, including fungal infections and hyperpigmentation disorders like melasma, as well as treatments for seborrheic keratoses. The company employs a unique discovery platform that utilizes its skin microbiome library, integrating prebiotics, probiotics, and postbiotics to develop innovative topical therapies with defined mechanisms of action.
Pillo Health
Series A in 2019
Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.
Wild Earth
Series A in 2019
Wild Earth is a technology startup based in Berkeley, California, that focuses on creating sustainable protein pet foods for dogs and cats. Founded in 2017, the company aims to transform the pet food industry by developing healthier, environmentally friendly, and humane alternatives to conventional products. Utilizing innovative technology, Wild Earth produces clean protein formulations that meet the nutritional needs of pets, ensuring their health and well-being while promoting a more sustainable approach to pet nutrition.
BillionToOne
Series A in 2019
BillionToOne Inc. is a precision diagnostics company focused on developing advanced genetic testing platforms that detect and quantify diseases at the molecular level. Established in 2016 and headquartered in Menlo Park, California, the company offers a noninvasive prenatal screening solution called UNITY, which analyzes fetal cell-free DNA from a single blood sample provided by the mother. This test can identify single-gene disorders such as cystic fibrosis, spinal muscular atrophy, and thalassemia, thereby providing a safer alternative to invasive procedures like amniocentesis. Beyond prenatal diagnostics, BillionToOne is also developing oncology assays that enable the detection of actionable mutations and monitor tumor burden through blood samples, allowing for more precise therapy selection and monitoring. The company's innovative technologies aim to make genetic testing both accurate and accessible, ensuring that a broader spectrum of patients can benefit from advanced medical diagnostics.
Qulab Inc. is a Los Angeles-based company founded in 2017 that specializes in automating drug design processes. By integrating advanced technologies such as computational chemistry, artificial intelligence, and quantum computing, Qulab aims to transform research and development in the chemical and pharmaceutical sectors. The company's innovative approach streamlines the design of small molecule medications, enhancing efficiency and accuracy in the drug development pipeline.
uLab Systems
Series B in 2018
uLab Systems Inc. is a technology company specializing in digital dental treatment planning for orthodontists. Established in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, uLab has developed a sophisticated software platform that allows orthodontists to create customized treatment plans and aligner movement strategies. The company's proprietary technology employs artificial intelligence and fully automated features, enabling orthodontists to efficiently generate chairside treatment plans in under five minutes. This innovation not only streamlines the treatment process but also helps in reducing lab fees and expediting the delivery of custom aligners. Through its solutions, uLab Systems enhances the efficiency and effectiveness of orthodontic care.
Curai Health
Series A in 2018
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.
Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, founded in 2015. The company specializes in the development of a novel technology that allows for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. Evonetix aims to enhance DNA synthesis accuracy and scalability, making it accessible to researchers and transforming how DNA is produced and utilized for gene synthesis. With a highly experienced engineering team that combines expertise from various scientific and engineering disciplines, Evonetix is positioned to significantly impact the capabilities of synthetic biology by enabling applications that were previously unfeasible.
Alveo Technologies, Inc., established in 2014 and based in Alameda, California, specializes in developing infectious disease diagnostic devices. The company's core product, be.well, is a comprehensive system that includes nasal swabs, disposable cartridges, a handheld analyzer, and a cloud-based diagnostics platform. This integrated platform combines nucleic acid detection with molecular biochemistry to identify illnesses such as Flu A/B, COVID-19, and Respiratory Syncytial Virus (RSV). By leveraging cutting-edge advances in sensing, microfluidics, and bioassays, Alveo aims to empower consumers, healthcare professionals, and treatment providers with faster, more informed decisions, ultimately contributing to better health outcomes and personalized medicine.
Singular Bio
Seed Round in 2017
Singular Bio, Inc. is a San Francisco-based company established in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a proprietary platform for single molecule analysis of DNA, which enables highly sensitive detection of various common health conditions. Singular Bio’s technology combines advanced optical methods with custom molecular biology and chemistry, allowing for cost-effective and rapid screening processes. The company's mission is to broaden access to essential healthcare information by making advanced genetic testing widely available, ultimately facilitating early detection and improved health outcomes for diverse populations. As of June 2019, Singular Bio operates as a subsidiary of Invitae Corporation.
Prellis Biologics
Seed Round in 2017
Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.
uLab Systems
Seed Round in 2017
uLab Systems Inc. is a technology company specializing in digital dental treatment planning for orthodontists. Established in 2015 and headquartered in Redwood City, California, with an additional office in Shanghai, China, uLab has developed a sophisticated software platform that allows orthodontists to create customized treatment plans and aligner movement strategies. The company's proprietary technology employs artificial intelligence and fully automated features, enabling orthodontists to efficiently generate chairside treatment plans in under five minutes. This innovation not only streamlines the treatment process but also helps in reducing lab fees and expediting the delivery of custom aligners. Through its solutions, uLab Systems enhances the efficiency and effectiveness of orthodontic care.
Manus Bio
Venture Round in 2017
Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.
Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.
Lemonaid Health
Series A in 2017
Lemonaid Health is an online telemedicine platform founded in 2013 and headquartered in San Francisco, California. The company aims to enhance the patient experience and optimize clinical care by utilizing advancements in machine learning and artificial intelligence. Its platform collects information on medical history, symptoms, current medications, and allergies, applying evidence-based guidelines to provide consumers with prescriptions. By offering healthcare services at a lower cost than typical co-pays, Lemonaid Health strives to make quality medical care more accessible to patients.
Rocket Pharmaceuticals
Venture Round in 2017
Rocket Pharmaceuticals, Inc. is a biotechnology company dedicated to developing innovative gene therapies for rare and severe pediatric diseases. The company specializes in lentiviral vector and adeno-associated virus platforms to target genetic disorders. Its lead program focuses on treating Fanconi Anemia, a serious condition that leads to bone marrow failure. In addition to this, Rocket is actively researching therapies for several other bone marrow-derived disorders, including Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-I, and Infantile Malignant Osteopetrosis. Furthermore, the company is developing an AAV-based gene therapy for Danon Disease, a multi-organ disorder associated with increased risk of cardiovascular complications. To advance its research, Rocket Pharmaceuticals maintains numerous collaborations and license agreements with prestigious institutions, enhancing its capabilities in gene therapy development. The company is headquartered in New York, New York.
Pillo Health
Seed Round in 2017
Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.
Multerra Bio
Seed Round in 2017
Multerra Bio, Inc. is a medical device company based in San Francisco, California, established in 2015. The company specializes in developing handheld diagnostic devices that utilize a single consumable cartridge to facilitate a wide range of clinical tests. These devices are designed to assist medical professionals in performing various diagnostic activities efficiently. Through its innovative approach, Multerra Bio aims to enhance the accuracy and convenience of medical diagnostics.